Tirzepatide
SURMOUNT-4
Eli Lilly · Phase 3 · Completed · Enrollment 783
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide (lead-in) | Obesity or overweight | n/r | 36 | n/r | n/r |
| Tirzepatide MTD | Obesity or overweight | n/r | 36 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 36 | n/r | n/r |